Occurrence of polycystic ovary syndrome and hyperadrogenemia in women with type 1 diabetes mellitus

Česká verzia

Authors: H. Kvasničková ¹; J. Vrbíková ¹; J. Hanáček ²; R. Bílek ¹; M. Hill ¹; D. Janíčková-Ždárská ³; K. Vondra ¹
Authors place of work: Endokrinologický ústav, Praha Ředitel: doc. MUDr. Vojtěch Hainer, CSc. ¹; Ústav pro péči o matku a dítě, Praha Ředitel: doc. MUDr. Jaroslav Feyereisl, CSc. ²; Interní klinika UK 2. LF a FN Motol, Praha Přednosta: prof. MUDr. Milan Kvapil, CSc., MBA ³
Published in the journal: Prakt. Lék. 2010; 90(4): 224-228
Category: Of different specialties

Summary

Female patients with type 1 diabetes mellitus (DM 1) frequently present with disorders of the menstrual cycle, among which are polycystic ovary syndrome (PCOS) and ovarial hyperandrogenism. We found PCOS corresponding to Rotterdam criteria in 24 % of 21 patients presenting with DM 1. This corresponds to data found by others. Laboratory hyperandrogenism was found in 38 % out of these 21 patients. This represents the upper frequency limit for this disease. In spite of the small number of patients, we found that there are significant differences in relationships between parameters of glycoregulation and androgens. Increased level of adrenal androgens (dehydroepiandrosterone sulphate) was related to lower levels of insulin dose (IU/kg/day) and to lower levels of glycaemia. On the contrary, an increase of testosterone, and its free fraction, was related to higher glycaemia and to high glycosylated haemoglobin (HbA1c) in the group of patients with isolated laboratory hyperandrogenemia.

These findings have been scarcely reported and our findings show that PCOS and hyperandrogenemia in female patients with DM 1 have a strong impact on metabolic control of diabetes mellitus.

Key words:
type 1 diabetes mellitus, polycystic ovary syndrome, hyperandrogenism, dehydroepiandrosterone sulphate, testosterone.

Zdroje

1. Adams, J., Tailor, A.E., Crowley, W.F. et al. Polycystic ovary morphology with regular ovulatory cycles: Insights into the pathophysiology of polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 2004, 89(9), p. 4343-4350.

2. Azziz, R., Waggoner, W.T., Ochoa, T. et al. Idiopathic hirsutism: an uncommon cause of hirsutism in Alabama. Fertil. Steril. 1998, 70, p. 274-278.

3. Broekmans, F.J., Knau, E.A., Valkenburg, O. et al. PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. Bjog 2006, 113, p. 1210-1217.

4. Cara, J.F., Rosenfield, R.L. Insulin-like growth factor I and insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells. Endocrinology 1988, 123, p.733-739.

5. Carmina, E. Ovarian and adrenal hyperandrogenism. Ann. NY Acad. Sci. 2006, 1092, p. 130-137.

6. Cibula, D., Henzl, M.R., Živný, J. a kol. Základy gynekologické endokrinologie. Praha: Grada, 2002.

7. Cibula, D., Hill, M., Starka, L. The Best correlation of the new index of hyperandrogenism with the grade of increased body hair. Eur. J. Endocrinol. 2000, 143, p. 405-408.

8. Codner, E., Escobar-Morreale, H.F. Clinical review: Hyperandrogenism and polycystic ovary syndrome in women with type 1 diabetes mellitus. J. Clin. Endocrinol. Metab. 2007, 92(4), p. 1209-1216.

9. Codner, E., Iniguez, G., Villarroel, C.. et al. Hormonal profile in women with polycystic ovaria syndrome with or without type 1 diabetes mellitus. J. Clin. Endocrinol. Metab. 2007, 92(12), p. 4742-4746.

10. Codner, E., Soto, N., Lope, P. Diagnostic criteria for polycystic ovary syndrome and ovaria morfology in woman with type 1 diabetes mellitus. J. Clin. Endocrinol. Metab. 2006, 91(6), p. 2250-2256.

11. Corbould, A. Effects of of androgens on insulin action in women: is androgen excess a component of female metabolic syndrome? Diabetes Metab. Res. Rev. 2008, 24(7), p. 520-532.

12. Dunaif, A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrine Reviews 1997, 18(6), p. 774-800.

13. Escobar-Morreale, H.F., Roldan, B., Barrio, R. et al. High prevalence of the polycystic ovary syndrome and hirsutism in women with type 1 diabetes mellitus. J. Clin. Endocrinol. Metab. 2000, 85, p. 4182-4187.

14. Hampl, R., Stárka, L. Dehydroepiandrosteron - „hormon mládí“. In: Aktuální endokrinologie. Praha: Galen, 1999.

15. Knochenhauer, E.S., Key, T.J., Kashar-Miller, M. et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J. Clin. Endocrinol. Metab. 1998, 83, p. 3078-3082.

16. Laven, J.S., Imani, B., Eijkemans, M.J. et al. New approaches to PCOS and other forms of anovulation. Obstet. Gynecol. Surv. 2002, 57, p. 755-767.

17. Loviselli, A., Pisanu, P., Cossu, E. et al. Low levels of dehydroepiandrosterone sulfate in adult males with insulin-dependent diabetes mellitus. Minerva Endocrinol. 1994, 19(3), p. 113-119.

18. Loretsky, L., Cataldo, N.A., Rosenwaks, Z., Giudice, L.C. The insulin-related ovaria regulatory system in health and disease. Endocr. Rev. 1999, 20(4), p. 535-582.

19. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). The Rotterdam ESHRE/ASRM - sponsored PCOS consensus workshop ground. Hum. Reprod. 2004, 19(1), p. 41- 47.

20. Roldan, B., Escobar-Morreale, H.F., Barrio, R. et al. Identification of the source of androgen excess in hyperandrogenic type 1 diabetic patients. Diabetes Care 2001, 24, p. 1297-1299.

21. Snajdrova, M., Martinek, J., Horejší, J. et al. Premenarchal and postmenarchal girls with insulin-dependent diabetes mellitus: ovarian and other organ-specific autoantibodies, menstrual cycle. J. Pediatr. Adolesc. Gynecol. 1999, 12(4), p. 209-214.

22. Speroff, L., Glass, R.H., Kase, N.G. Clinical gynecologic endocrinology and infertility. 7th edition. Lippincott Williams and Wilkins, 2005.

23. Vondra, K., Hampl, R., Němcová, D. a kol. Vztah některých steroidů, SHBG, IGF-1, IGF BP-3 a růstového hormonu ke glykoregulaci při dlouhodobé léčbě nízkými dávkami glukokortikoidů. Čas. lék. čes., 2002, 141(3), s. 89-95.

24. Yildiz, B.O., Azziz, R. The adrenal and polycystic ovary syndrome. Rev. Endocr. Metab. Disord. 2007, 8(4), p. 331-342.

25. Yki-Jarvinen, H., Makimattila, S., Utriainen, T. et al. Portal insulin concentrations rather than insulin sensitivity regulate serum sex hormone binding globulin and insulin-like growth factor binding protein 1 in vivo. J. Clin. Endocrinol. Metab. 1995, 80, p. 3227-3232.

26. Yki-Jarvinen, H., Koivisto, V.A. Natural course of insulin resistance in type I diabetes. N. Engl. J. Med. 1986, 315, p. 224-230.